Sucampo Pharmaceuticals CEO Ryuji Ueno Unloads 360,000 Shares (SCMP)
Sucampo Pharmaceuticals (NASDAQ:SCMP) CEO Ryuji Ueno sold 360,000 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $10.36, for a total value of $3,729,600.00. Following the sale, the chief executive officer now directly owns 148,530 shares of the company’s stock, valued at approximately $1,538,771. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 0.56% on Wednesday, hitting $10.58. The stock had a trading volume of 241,135 shares. Sucampo Pharmaceuticals has a 1-year low of $4.55 and a 1-year high of $11.00. The stock has a 50-day moving average of $8.82 and a 200-day moving average of $6.98. The company has a market cap of $442.9 million and a price-to-earnings ratio of 25.09.
A number of analysts have recently weighed in on SCMP shares. Analysts at Cantor Fitzgerald cut their price target on shares of Sucampo Pharmaceuticals from $11.00 to $10.00 in a research note to investors on Thursday, November 7th. They now have a “buy” rating on the stock. Analysts at Zacks upgraded shares of Sucampo Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, November 6th. They now have a $7.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $9.20.
Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.